Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
778
Shown on this page
12
Current sort
Recently updated
Campus scope
Weill Cornell Medicine, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Weill Cornell Medicine, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 385–396 of 778 matching trials with a site at Weill Cornell Medicine, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT06693531
Site status not listed — check the official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
54
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT06313593
Site status not listed — check the official record
Conditions
Myeloproliferative Neoplasms
Interventions
INCB160058, Standard disease-directed therapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Palo Alto, California • Tampa, Florida + 8 more
Recruiting Not applicable Interventional Accepts healthy volunteers

Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder

NCT05675735
Status at this site: Recruiting
Conditions
Problems Related to Social Environment
Interventions
Clinic-Level Multidimensional Intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
4
States / cities
Storrs, Connecticut • Buffalo, New York • New York, New York
Conditions
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cystoscopy, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab, Transurethral Resection of Bladder Tumor
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
381
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 257 more
Active, not recruiting Phase 2 Interventional

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

NCT05090358
Site status not listed — check the official record
Conditions
Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
Interventions
Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin
Dietary Supplement · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Primary Care Screening and Intervention for Patients With Dementia and Caregivers

NCT07758738
Site status not listed — check the official record
Conditions
Dementia, Elder Abuse, Elder Mistreatment
Interventions
SIRENS application, SIRENS screening
Behavioral · Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years and older
Enrollment
774 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Metformin in Alzheimer's Dementia Prevention

NCT04098666
Site status not listed — check the official record
Conditions
Mild Cognitive Impairment
Interventions
Placebo oral tablet, extended release metformin
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
22
States / cities
Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961
Site status not listed — check the official record
Conditions
Atopic Dermatitis
Interventions
Afimkibart, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
21
States / cities
Fremont, California • Los Angeles, California • Fort Myers, Florida + 16 more
Conditions
Ovarian Carcinoma
Interventions
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
Procedure · Other
Lead sponsor
NRG Oncology
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2047
U.S. locations
564
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
Recruiting Not applicable Interventional

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

NCT05230173
Status at this site: Recruiting
Conditions
Ulcerative Colitis, Crohn Disease
Interventions
Pragmatic
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 20 more
Active, not recruiting Phase 1Phase 2 Interventional

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT00392353
Site status not listed — check the official record
Conditions
Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Ring Sideroblasts, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia
Interventions
Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
7
States / cities
Chicago, Illinois • Baltimore, Maryland • Manhasset, New York + 2 more
Active, not recruiting Not applicable Interventional

Cryoablation for Monomorphic Ventricular Tachycardia

NCT05675865
Site status not listed — check the official record
Conditions
Sustained VT
Interventions
cryoablation procedure
Device
Lead sponsor
Adagio Medical
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • San Francisco, California • Baltimore, Maryland + 9 more

About this Weill Cornell Medicine institution page

What this page lists
ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.